Pharma 5 launches Moroccan cannabidiol at half the price
By the AFREEQUE newsroom, based on Santé Mag (Maroc)
Moroccan laboratory Pharma 5 presented its generic cannabidiol in Casablanca on 12 November 2026 for severe drug-resistant epilepsy, announced at 50% less than the reference medicine. It claims two national firsts: producing an active substance from legally cultivated cannabis in Morocco and manufacturing the medicine from it, according to Santé Mag.
Moroccan pharmaceutical laboratory Pharma 5 presented Cannabidiol Pharma 5 in Casablanca on Thursday 12 November 2026, a generic cannabidiol-based medicine intended to treat certain severe forms of drug-resistant epilepsy. Its announced price is 50% lower than that of the reference medicine. A 100 ml presentation is priced at 5,498 dirhams, while reimbursement for the treatment remains pending.
The medicine comes as an oral solution dosed at 100 mg/ml and contains purified cannabidiol. Its development required five years of industrial and pharmaceutical work. Pharma 5 claims the national production of the active substance derived from cannabis legally cultivated in Morocco, in accordance with the requirements of the European Pharmacopoeia, as well as the manufacture of the medicine from this raw material.
The project is based on an integrated supply chain involving more than 200 million dirhams in investment and several dozen farming families. The laboratory worked with the National Agency for the Regulation of Cannabis-Related Activities (ANRAC), the Moroccan Agency for Medicines and Health Products (AMMPS) and the Mohammed VI Foundation for Science and Health (FM6SS).
The launch fulfils a project announced nearly two years earlier. Pharma 5 had already announced its intention to produce pharmaceutical cannabidiol in Morocco, before the official presentation of the medicine.
